BrainsWay/$BWAY

1D1W1MYTD1Y5YMAX

About BrainsWay

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
Ticker
$BWAY
Sector
Health
Primary listing
NASDAQ
Employees
129
Headquarters
Jerusalem, Israel
Website
www.brainsway.com

BrainsWay Metrics

BasicAdvanced
$509M
54.94
$0.23
0.08
-

Bulls say / Bears say

Q2 revenue rose 35% year on year to $17.1 million, while adjusted EBITDA more than doubled to $3.5 million. Record shipments and stronger margins led BrainsWay to raise 2026 revenue guidance to $68 million-$70 million, implying 30%-34% growth. (Markets Insider, The Motley Fool)
Coverage for the accelerated SWIFT protocol has expanded across eight major US payers and the Department of Veterans Affairs, representing more than 57 million covered lives. Broader reimbursement could reduce a key barrier to provider adoption and patient access. (BrainsWay)
A multisite randomised controlled study reported rapid antidepressant effects and sustained longer-term outcomes for SWIFT, which cuts acute-phase clinic visits by 70% versus traditional treatment. If these results translate into wider clinical use, the shorter protocol could strengthen BrainsWay’s differentiation and improve clinic capacity. (OTC Markets)
The company faces growing competition from other TMS providers and potential psychedelic treatments, while the addressable market may not expand quickly enough to sustain its recent growth. Continued momentum may therefore depend on successful new indications or acquisitions. (Seeking Alpha)
BrainsWay’s strong operating performance has been accompanied by a valuation that already assumes substantial future growth. A high earnings multiple leaves less room for disappointment if shipments, margins or guidance weaken. (Seeking Alpha, GuruFocus)
Expansion into PTSD and other indications remains subject to regulatory and clinical risk. BrainsWay’s recent PTSD evidence was preliminary, subject to peer review, and the treatment was not yet FDA-cleared for PTSD or comorbid PTSD and depression. (BrainsWay, Healio)
Data summarised monthly by Lightyear AI. Last updated on 20 Sept 2026.

BrainsWay Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

BrainsWay Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

BrainsWay News

AllArticlesVideos

Brainsway Q2 Earnings Call Highlights

MarketBeat2 months ago

Funds containing BrainsWay

AllUSDEURGBP
Funds
Fund name
Fund size
$BWAY weighting
iShares Healthcare Innovation$HEAL
$1.4B0.05%
iShares Healthcare Innovation€2B78
€1.2B0.05%
iShares Ageing Population€AGED
€822M0.05%
iShares Healthcare Innovation£DRDR
£1B0.05%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.